Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 88
Filtrar
Más filtros

Base de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
J Clin Pharmacol ; 53(12): 1334-40, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24030903

RESUMEN

Global introspection is considered an unreliable method for attribution of causality of serious adverse events (SAEs), yet remains widely used for cancer drug clinical trials. Here, we compare structured case abstraction (SCA) to the routine method for detecting, evaluating, and reporting ADEs during cancer drug clinical trials to an Institutional Review Board (IRB). We obtained all SAE reports (2001-2008) received by one IRB for six clinical trials involving bevacizumab or oxaliplatin for treatment of gastrointestinal cancers. We compared the routine IRB SAE method to SCA for adverse event detection and causality attribution. Of 205 adverse events, 182 events (75%) were not reported; of these, 6 (20%) of 30 SAEs requiring an IRB report were unreported. For the 10 item Naranjo score, the amount of information useful for causality attribution was higher with SCA than the routine method (6.0 vs. 2.4 items, P < .0001). One-fifth of SAEs requiring an IRB report were unreported to the IRB via the routine method. SCA provided more useful information as to whether an SAE was caused by a cancer drug exposure. Our results suggest that SCA may improve SAE detection and the accuracy of attribution of causality during cancer drug clinical trials.


Asunto(s)
Sistemas de Registro de Reacción Adversa a Medicamentos , Anticuerpos Monoclonales Humanizados/efectos adversos , Antineoplásicos/efectos adversos , Neoplasias Colorrectales/tratamiento farmacológico , Compuestos Organoplatinos/efectos adversos , Neoplasias Pancreáticas/tratamiento farmacológico , Bevacizumab , Ensayos Clínicos como Asunto , Comités de Ética en Investigación , Humanos , Oxaliplatino , Estados Unidos
2.
Clin Pharmacol Ther ; 88(2): 231-6, 2010 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-20571489

RESUMEN

The validity of information regarding drug toxicity in humans depends on the quality of the methods and instruments used to assess adverse drug events (ADEs). This study evaluates the quality of instruments used to assess and report ADEs to institutional review boards (IRBs) at US cancer centers. Forms from all 49 National Cancer Institute (NCI)-designated centers were assessed for utility in abstracting event type, severity, and causality; patient demographics; safety monitoring; and consequent changes in the conduct of the relevant study. Of the 55 items considered essential for ADE reporting, one item (event description) was present on all the forms. Seventy-eight percent of the instruments prompted for global introspection of the investigator, a method known to be unreliable. Of the 34 items that our panel of experts considered essential for event description, the median number of items present was four (domain = 1-11). The use of a validated tool to describe and assess event type, severity, and causality may lead to more timely, accurate identification of safety signals in cancer treatment.


Asunto(s)
Sistemas de Registro de Reacción Adversa a Medicamentos/estadística & datos numéricos , Antineoplásicos/efectos adversos , Causalidad , Ensayos Clínicos como Asunto , Interpretación Estadística de Datos , Humanos , National Cancer Institute (U.S.) , Pacientes , Proyectos de Investigación , Factores Socioeconómicos , Estados Unidos
3.
Clin Pharmacol Ther ; 84(3): 385-92, 2008 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-18388884

RESUMEN

A prescription is a health-care program implemented by a physician or other qualified practitioner in the form of instructions that govern the plan of care for an individual patient. Although the algorithmic nature of prescriptions is axiomatic, this insight has not been applied systematically to medication safety. We used software design principles and debugging methods to create a "Patient-oriented Prescription for Analgesia" (POPA), assessed the rate and extent of adoption of POPA by physicians, and conducted a statistical process control clinical trial and a subsidiary cohort analysis to evaluate whether POPA would reduce the rate of severe and fatal opioid-associated adverse drug events (ADEs). We conducted the study in a population of 153,260 hospitalized adults, 50,576 (33%) of whom received parenteral opioids. Hospitalwide, the use of POPA increased to 62% of opioid prescriptions (diffusion half-life = 98 days), while opioid-associated severe/fatal ADEs fell from an initial peak of seven per month to zero per month during the final 6 months (P < 0.0016) of the study. In the nested orthopedics subcohort, the use of POPA increased the practice of recording pain scores (94% vs. 72%, P < 0.00001) and the use of adjuvant analgesics (95% vs. 40%, P < 0.00001) and resulted in fewer opioid-associated severe ADEs than routine patient-controlled analgesia (PCA) (0% vs. 2.7%, number needed to treat (NNT) = 35, P < 0.015). The widespread diffusion of POPA was associated with a substantial hospitalwide decline in opioid-associated severe/fatal ADEs.


Asunto(s)
Analgesia Controlada por el Paciente/métodos , Analgésicos Opioides/administración & dosificación , Analgésicos Opioides/efectos adversos , Errores de Medicación/prevención & control , Errores de Medicación/estadística & datos numéricos , Dolor/tratamiento farmacológico , Atención Dirigida al Paciente/métodos , Adulto , Anciano , Glucemia/efectos de los fármacos , Carbamatos/farmacocinética , Carbamatos/farmacología , Ensayos Clínicos como Asunto , Interacciones Farmacológicas , Femenino , Gemfibrozilo/farmacocinética , Gemfibrozilo/farmacología , Mortalidad Hospitalaria , Humanos , Hipoglucemiantes/farmacocinética , Hipoglucemiantes/farmacología , Hipolipemiantes/farmacocinética , Hipolipemiantes/farmacología , Masculino , Persona de Mediana Edad , Estudios Multicéntricos como Asunto , Dolor/clasificación , Piperidinas/farmacocinética , Piperidinas/farmacología , Programas Informáticos
4.
Bone Marrow Transplant ; 39(7): 425-9, 2007 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-17310132

RESUMEN

Zygomycosis is increasingly reported as a cause of life-threatening fungal infections. A higher proportion of cases reported over the last decades have been in cancer patients, with or without hematopoietic stem cell transplantation (HSCT). The new anti-fungal agent voriconazole is a recently identified risk factor for developing zygomycosis. We reviewed the clinical characteristics and outcomes of a large cohort of cancer patients who developed zygomycosis after exposure to voriconazole. Health care professionals at 13 large cancer centers provided clinical information on cancer patients with zygomycosis and prior exposure to voriconazole. Criteria for inclusion were 5 days or more of voriconazole use and diagnostic confirmation with tissue or histology. Fifty-eight cases were identified among patients with hematologic malignancies, 62% including patients who underwent a HSCT procedure. Fifty-six patients received voriconazole for primary or secondary prophylaxis against fungal infection. In addition to prior exposure to voriconazole, patients also had several of the previously established risk factors for zygomycosis. Amphotericin B was the most commonly prescribed anti-fungal therapy. Overall mortality was 73%. We conclude that zygomycosis after exposure to voriconazole is a recently described entity that is frequently fatal, despite treatment with currently available anti-fungal agents and surgery.


Asunto(s)
Neoplasias Hematológicas/tratamiento farmacológico , Neoplasias Hematológicas/terapia , Trasplante de Células Madre Hematopoyéticas/métodos , Pirimidinas/administración & dosificación , Triazoles/administración & dosificación , Cigomicosis/epidemiología , Cigomicosis/etiología , Adolescente , Adulto , Anciano , Anfotericina B/uso terapéutico , Niño , Preescolar , Femenino , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Voriconazol
5.
J Gen Intern Med ; 16(9): 583-9, 2001 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-11556938

RESUMEN

OBJECTIVE: To determine whether older age continues to influence patterns of care and in-hospital mortality for hospitalized persons with HIV-related Pneumocystis carinii pneumonia (PCP), as determined in our prior study from the 1980s. DESIGN: Retrospective chart review. PATIENTS/SETTING: Patients (1,861) with HIV-related PCP at 78 hospitals in 8 cities from 1995 to 1997. MEASUREMENTS: Medical record notation of possible HIV infection; alveolar-arterial oxygen gradient; CD4 lymphocyte count; presence or absence of wasting; timely use of anti-PCP medications; in-hospital mortality. MAIN RESULTS: Compared to younger patients, patients > or =50 years of age were less likely to have HIV mentioned in their progress notes (70% vs 82%, P <.001), have mild or moderately severe PCP cases at admission (89% vs 96%, P <.002), receive anti-PCP medications within the first 2 days of hospitalization (86% vs 93%, P <.002), and survive hospitalization (82% vs 90%, P <.003). However, age was not a significant predictor of mortality after adjustment for severity of PCP and timeliness of therapy. CONCLUSIONS: While inpatient PCP mortality has improved by 50% in the past decade, 2-fold age-related mortality differences persist. As in the 1980s, these differences are associated with lower rates of recognition of HIV, increased severity of illness at admission, and delays in initiation of PCP-specific treatments among older individuals--factors suggestive of delayed recognition of HIV infection, pneumonia, and PCP, respectively. Continued vigilance for the possibility of HIV and HIV-related PCP among persons > or =50 years of age who present with new pulmonary symptoms should be encouraged.


Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/mortalidad , Terapia Antirretroviral Altamente Activa , Neumonía por Pneumocystis/mortalidad , Infecciones Oportunistas Relacionadas con el SIDA/terapia , Factores de Edad , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Neumonía por Pneumocystis/inmunología , Neumonía por Pneumocystis/terapia , Calidad de la Atención de Salud , Estudios Retrospectivos , Índice de Severidad de la Enfermedad
6.
Am J Rhinol ; 15(1): 49-53, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11258656

RESUMEN

An association between chronic sinusitis and asthma has been noted for many years, although the precise nature of the relationship is poorly understood. Earlier studies, using traditional surgical techniques, have demonstrated subjective improvement in asthmatic complaints. Reports demonstrating improvement following endoscopic sinus surgery for chronic sinusitis are rare. To report our experience with endoscopic sinus surgery and asthmatics, we reviewed the charts of 75 consecutive patients with asthma and chronic sinusitis who underwent endoscopic sinus surgery between 1994 and 1996. Study criteria included the following: chronic sinusitis, one year preoperative and one year postoperative follow-up from endoscopic sinus surgery, and asthma requiring inhaled steroids and oral prednisone for control. Many patients required prednisone bursts for control of asthma. Number of days and total dose of oral prednisone were used as objective measures of asthma control. Number of weeks of antibiotics was used as a relative measure of sinusitis. Fourteen of the 15 patients meeting study criteria decreased their postoperative prednisone requirement by total number of days (preoperative 84 versus postoperative 63 days [p < 0.0001]). Postoperatively, patients required an average of 1300 mg less oral prednisone (p < 0.033). Antibiotic use also decreased, with an average use of antibiotic nine weeks preoperatively versus seven weeks postoperatively (p < 0.045). This study provides corroborative objective evidence that, at least in the short term, endoscopic sinus surgery is efficacious in the management of patients with chronic sinusitis and asthma.


Asunto(s)
Asma/complicaciones , Asma/tratamiento farmacológico , Endoscopía/métodos , Sinusitis/complicaciones , Sinusitis/cirugía , Adolescente , Adulto , Anciano , Antibacterianos/uso terapéutico , Antiinflamatorios/uso terapéutico , Asma/clasificación , Enfermedad Crónica , Quimioterapia Combinada , Utilización de Medicamentos , Endoscopía/efectos adversos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Prednisona/uso terapéutico , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Factores de Tiempo , Resultado del Tratamiento
7.
Pediatr Dermatol ; 18(6): 473-7, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11841630

RESUMEN

Over the past two decades there have been significant efforts in the United States to heighten awareness about skin cancer. Our goal was to assess parental knowledge, practice, and source of information about sun protection for their children. A questionnaire was administered to 158 parents of children at a dermatology clinic and 96 parents of children at a pediatric clinic (n=254). The survey included four parts: demographics, knowledge about skin cancer, sun protection practices, and sources of sun protection information. The mean knowledge score was 61% correct. Independent predictors of a higher score were fewer children and being a health care or other professional (p < 0.03). Independent predictors of parental sunscreen use were higher knowledge score, younger age, and fewer lifetime sunburns (p < 0.03); predictors of sunscreen use for children were higher knowledge score and fairer skin (p < 0.03). The top sources of sun protection information ranked by respondents were television and magazines; the top desired sources were primary care physicians and dermatologists. The knowledge results suggest the need for increased education about skin cancer prevention. Because the media is a major information source, it is important to ensure that messages about sun risks/protection are correct. The respondents' desire to learn more from primary care physicians emphasizes the need to educate physicians about sun protection.


Asunto(s)
Conocimientos, Actitudes y Práctica en Salud , Neoplasias Inducidas por Radiación/prevención & control , Padres/psicología , Neoplasias Cutáneas/prevención & control , Luz Solar/efectos adversos , Niño , Educación en Salud , Humanos , Análisis Multivariante , Protección Radiológica , Factores de Riesgo , Factores Socioeconómicos , Encuestas y Cuestionarios
8.
Respir Med ; 94(10): 964-70, 2000 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11059949

RESUMEN

Occupational immunological lung disease, due to low molecular weight, reactive chemicals such as trimellitic anhydride (TMA), is an emerging health problem. If there were a marker that was highly predictive of the ability of the immune system to recognize TMA as an allergen, better prevention strategies could be employed with at risk individuals. The purpose of this study is to evaluate whether human leucocyte antigen (HLA) class specificity is associated with the development of late respiratory systemic syndrome (LRSS) or asthma due to immunological sensitivity to trimellitic anhydride (TMA). This is a case control study of 17 individuals with LRSS, 12 with asthma and 22 TMA similarly exposed individuals who did not develop LRSS or asthma. Comparing the sensitized individuals (LRSS or asthma) with the non-sensitized individuals (controls), we found no difference in frequency of any HLA antigen. In summary, the lack of association of HLA antigens with LRSS or asthma due to TMA suggests that these will not be useful markers to identify at risk individuals.


Asunto(s)
Alérgenos/efectos adversos , Asma/diagnóstico , Antígenos HLA/análisis , Enfermedades Profesionales/diagnóstico , Anhídridos Ftálicos/efectos adversos , Trastornos Respiratorios/diagnóstico , Adulto , Asma/inducido químicamente , Asma/inmunología , Biomarcadores/análisis , Estudios de Casos y Controles , Femenino , Humanos , Inmunoglobulina E/sangre , Inmunoglobulina G/sangre , Masculino , Enfermedades Profesionales/inducido químicamente , Enfermedades Profesionales/inmunología , Exposición Profesional/efectos adversos , Trastornos Respiratorios/inducido químicamente , Trastornos Respiratorios/inmunología
9.
J Allergy Clin Immunol ; 106(5): 973-80, 2000 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11080723

RESUMEN

BACKGROUND: The frequency of reactions reported to occur after the consumption of monosodium glutamate (MSG) is the subject of controversy. OBJECTIVE: We conducted a multicenter, multiphase, double-blind, placebo-controlled study with a crossover design to evaluate reactions reportedly caused by MSG. METHODS: In 3 of 4 protocols (A, B, and C), MSG was administered without food. A positive response was scored if the subject reported 2 or more symptoms from a list of 10 symptoms reported to occur after ingestion of MSG-containing foods within 2 hours. In protocol A 130 self-selected reportedly MSG-reactive volunteers were challenged with 5 g of MSG and with placebo on separate days (days 1 and 2). Of the 86 subjects who reacted to MSG, placebo, or both in protocol A, 69 completed protocol B to determine whether the response was consistent and dose dependent. To further examine the consistency and reproducibility of reactions to MSG, 12 of the 19 subjects who responded to 5 g of MSG but not to placebo in both protocols A and B were given, in protocol C, 2 challenges, each consisting of 5 g of MSG versus placebo. RESULTS: Of 130 subjects in protocol A, 50 (38. 5%) responded to MSG only, 17 (13.1%) responded to placebo only (P <. 05), and 19 (14.6%) responded to both. Challenge with increasing doses of MSG in protocol B was associated with increased response rates. Only half (n = 19) of 37 subjects who reacted to 5 g of MSG but not placebo in protocol A reacted similarly in protocol B, suggesting inconsistency in the response. Two of the 19 subjects responded in both challenges to MSG but not placebo in protocol C; however, their symptoms were not reproducible in protocols A through C. These 2 subjects were challenged in protocol D 3 times with placebo and 3 times with 5 g of MSG in the presence of food. Both responded to only one of the MSG challenges in protocol D. CONCLUSION: The results suggest that large doses of MSG given without food may elicit more symptoms than a placebo in individuals who believe that they react adversely to MSG. However, neither persistent nor serious effects from MSG ingestion are observed, and the responses were not consistent on retesting.


Asunto(s)
Hipersensibilidad a los Alimentos/etiología , Glutamato de Sodio/efectos adversos , Adulto , Estudios Cruzados , Femenino , Hipersensibilidad a los Alimentos/fisiopatología , Humanos , Masculino , Persona de Mediana Edad , Síndrome
10.
Am J Respir Crit Care Med ; 162(2 Pt 1): 393-8, 2000 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-10934059

RESUMEN

In the early 1990s, hospital survival among patients with human immunodeficiency virus (HIV)-related Pneumocystis carinii pneumonia (PCP) and respiratory failure was poor, approximately 20%. We examined ICU use and outcomes for patients with acute respiratory failure from PCP from 1995 to 1997. We conducted a retrospective medical record review using a random sample of 71 hospitals in seven regions of the United States. Among 1,660 patients with confirmed or presumed PCP, 155 (9%) received mechanical ventilation for respiratory failure. Factors that predicted use of mechanical ventilation, independent of severity of illness on hospital admission, included African-American ethnicity and geographic location (p

Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/complicaciones , Neumonía por Pneumocystis/complicaciones , Insuficiencia Respiratoria/mortalidad , Enfermedad Aguda , Femenino , Humanos , Masculino , Neumonía por Pneumocystis/terapia , Pronóstico , Distribución Aleatoria , Respiración Artificial , Insuficiencia Respiratoria/etiología , Insuficiencia Respiratoria/terapia , Estudios Retrospectivos , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA